News and Announcements
IND Submission to FDA for IW-2143 (BNC210) Anti-Anxiety Drug Candidate
- Published November 28, 2012 4:21PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bionomics Limited (ASX: BNO) (ADR: BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc that an Investigational New Drug (IND) application was submitted to the US Food and Drug Administration (FDA) for a clinical trial of anti-anxiety drug candidate IW-2143.
Ironwood intends to initiate Phase I studies with IW-2143 in healthy volunteers following the filing of the IND by the FDA. The initial Phase I US trial is designed to further assess IW-2143’s pharmacokinetics.
—–
To view the full article, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
